Eli Lilly
American pharmacist, Union Army officer, businessman, philanthropist
Entity sentiment
Events
01.07.2024Labour Party wins the general election
01.07.2024Labour Party wins the general election
Express your sentiment!
Related
News
Opinions
Statements
business 2025-05-08 00:00
Trump announces new trade deal with the UK boosting market optimism - The U.S. stock market experienced a surge following President Donald Trump's announcement of a new trade deal with the UK.
- Optimism about potential tariff de-escalation and a favorable economic backdrop contributed to increased trading activity.
- Overall, the announcement signifies a positive shift in trade relations, impacting markets and investor sentiment.
00
business 2025-05-07 00:00
CVS health shifts to Wegovy, leaving Eli Lilly's Zepbound behind - CVS Health’s Caremark will prioritize Wegovy by Novo Nordisk on its formulary starting July 1, 2025.
- Zepbound by Eli Lilly will be removed from Caremark's formulary due to a negotiated lower price for Wegovy.
- Despite investor fears of a pricing war, analysts believe that both companies aim to enhance patient access rather than undercut one another.
00
business 2025-05-02 00:00
Eli Lilly defends market position after CVS partners with Novo Nordisk - Eli Lilly reported a 45% revenue increase in Q1 2025, surpassing expectations with a significant spike in sales of its GLP-1 franchise.
- Concerns have arisen regarding the partnership between CVS Health and Novo Nordisk, which may affect Eli Lilly's market share in the obesity treatment sector.
- Despite these challenges, analysts remain optimistic about Eli Lilly's long-term outlook and market strategy.
00
business 2025-05-01 00:00
Eli Lilly lowers profit outlook despite soaring sales from weight loss drugs - Eli Lilly reported a 45% year-over-year increase in first-quarter sales driven by demand for diabetes and weight loss drugs.
- The company lowered its adjusted earnings per share forecast for fiscal 2025 due to a significant charge related to a cancer drug acquisition.
- Despite strong sales, Eli Lilly's shares fell by 5% in premarket trading reflecting market reactions to its updated guidance.
00
business 2025-04-28 00:00
Boeing shares expected to soar after bullish analyst report - Boeing's shares increased nearly 2% due to a Bernstein analyst upgrade to outperform.
- The upgrade follows a series of controversies and manufacturing issues affecting Boeing.
- Analyst optimism suggests future growth for Boeing as they navigate a challenging industry landscape.
00
business 2025-04-28 00:00
HSBC downgrades Eli Lilly amid valuation concerns and stiff competition - HSBC downgraded Eli Lilly stock from "buy" to "reduce" and lowered its price target from $1,150 to $700 per share.
- The stock has risen about 15% in 2025, but there are concerns about high valuation and competition in the GLP-1 drugs market.
- The downgrade signals potential challenges ahead for Eli Lilly as investors reassess the stock's value amid competition.
00
business 2025-04-23 13:11
Pfizer scraps danuglipron's development after patient injury in trial - Pfizer announced it would terminate development of danuglipron after a trial patient suffered a liver injury.
- Eli Lilly is seeking FDA approval for an oral GLP-1 drug for weight loss and diabetes by 2026, despite known side effects.
- Lexaria's technology aims to reduce side effects and enhance drug performance in existing GLP-1 therapies.
00
business 2025-04-03 23:37
Eli Lilly CEO warns of declining UK life sciences reputation - David Ricks, CEO of Eli Lilly, commented on the long-term effects of Trump's tariffs on US manufacturing and tax revenues.
- Ricks expressed concerns about the UK's declining status in pharmaceuticals due to slow regulation and innovation disincentives.
- The imposition of tariffs may adversely affect investment in new medicines, highlighting the industry's critical concern for future development.
00
society 2025-03-28 14:31
European committee rejects Eli Lilly's Alzheimer’s drug over safety concerns - The European Medicines Agency committee rejected Eli Lilly's Alzheimer’s drug, Kisunla, due to safety concerns.
- The drug carries potential risks of brain bleeding and swelling, which were deemed significant.
- Eli Lilly plans to seek a re-examination of the decision while continuing discussions with the agency.
00
business 2025-02-06 14:22
Eli Lilly reveals earlier data release for new weight loss drug - Eli Lilly will provide late-stage data for retatrutide in 2025, earlier than prior expectations.
- The drug targets those with obesity and knee osteoarthritis, potentially surpassing the efficacy of existing treatments.
- The company aims to maintain its leadership in weight loss medications amid competition.
00
business 2025-01-14 00:00
Eli Lilly strikes deal for cancer treatment, gives timeline for weight loss pill - Eli Lilly cut its 2024 revenue guidance due to disappointing demand for its obesity and diabetes drugs.
- The company now expects revenue of about $45 billion for 2024, down from previous estimates of $45.4 to $46 billion.
- Despite the decrease in guidance, Eli Lilly plans to ramp up manufacturing capacity to meet future demand.
00
society 2024-12-20 21:44
FDA approval of Zepbound sparks debate over weight loss solutions - The FDA approved Zepbound, a weight loss drug, to treat obstructive sleep apnea in adults with obesity.
- The approval is based on clinical trials demonstrating significant weight loss and symptom reduction among participants.
- This development may lead to broader insurance coverage and increased awareness about sleep apnea and its health risks.
00
business 2024-12-06 08:16
Eli Lilly to invest $3 billion in controversial Wisconsin plant expansion - Eli Lilly is investing $3 billion to expand its manufacturing facility in Kenosha County, Wisconsin.
- The expansion is expected to create 750 high-skilled jobs and over 2,000 construction jobs.
- This initiative aims to enhance production capabilities to meet growing global demand for their diabetes and obesity drugs.
00
business 2024-12-04 15:21
Zepbound outperforms Wegovy in significant weight loss results - Clinical trial data indicated that Zepbound users lost an average of 50 pounds compared to 33 pounds for Wegovy users.
- A higher percentage of Zepbound users achieved significant weight loss milestones compared to those on Wegovy.
- The findings suggest that Zepbound may offer a more effective treatment option for obesity management.
00
politics 2024-11-26 00:00
Biden administration proposes coverage for obesity drugs through Medicare - The Biden administration proposed a rule change that would enable Medicare and Medicaid to cover obesity drugs starting in 2026.
- Eli Lilly's Zepbound is among the key treatments that may gain coverage under this new proposal.
- If implemented, this change could substantially enhance access to obesity treatments for millions of Americans.
00
science 2024-11-26 00:00
Amgen's obesity drug shows promise with 20% weight loss after one year - Amgen's experimental drug MariTide showed up to 20% weight loss in patients after a year.
- The drug can be administered monthly or less frequently, potentially offering a dosage advantage over weekly options.
- The results position MariTide as a strong competitor in the rapidly expanding obesity drug market.
00
society 2024-11-17 00:00
Eli Lilly urges UK to quickly adopt new weight-loss drugs - Eli Lilly is advocating for the NHS to revise its methods for calculating the value of drugs.
- The current evaluation system overlooks the economic and social benefits that treatments may provide.
- Failure to implement these changes could result in patients missing out on essential new medical treatments.
00
society 2024-10-14 09:43
FDA to Review Compounded Versions of Eli Lilly Weight Loss Drugs - The FDA is reassessing its ban on compounding pharmacies that produce cheaper versions of Eli Lilly's medications.
- Compounding groups have filed a complaint against the FDA, arguing that the ban harms patients needing vital treatments.
- Eli Lilly's actions against imitations of its drugs highlight the ongoing tension in the pharmaceutical industry regarding access to medications.
00
category, sub-category 2024-09-16 13:36
Eli Lilly receives FDA approval for eczema treatment Ebglyss - The FDA approved Ebglyss for patients aged 12 and older with moderate-to-severe eczema who have not responded to topical treatments.
- Clinical trials showed that 38% of participants achieved clear or almost clear skin after 16 weeks, with many also experiencing itch relief.
- This approval expands treatment options for eczema, offering hope for improved quality of life for affected patients.
00
society, science 2024-09-10 11:18
Efsitora alfa shows A1C reduction in type 2 diabetes patients - The QWINT-2 trial compared once-weekly insulin efsitora alfa to once-daily insulin degludec in insulin-naïve adults with type 2 diabetes.
- Participants using efsitora achieved an A1C below 7% and experienced 45 minutes more time in range per day without increased hypoglycemia risk.
- These findings suggest that efsitora could simplify diabetes management and improve adherence for patients requiring insulin therapy.
00
business, society 2024-08-27 00:00
Eli Lilly launches affordable Zepbound weight loss drug options - Eli Lilly has launched new single-dose vials of Zepbound at reduced prices to improve access for uninsured patients.
- The new vials require self-injection with a syringe, differing from the previous autoinjector format.
- This initiative aims to ensure patients receive genuine medication while addressing the rise of unregulated alternatives.
00
health, society, politics 2024-08-21 16:36
Bipartisan Lawmakers Demand FDA Inquiry into Clinical Trials in China - US representatives demand FDA to disclose details of drug trials in China.
- Accusations of Pfizer and Eli Lilly conducting drug testing on prisoners in Chinese concentration camps.
- Concerns raised about ethics and human rights violations in pharmaceutical research.
00
business 2024-08-20 00:00
Analyst Calls for Top Stocks - Top analyst calls made for Nvidia, Amazon, AMD, Exxon, and more on Tuesday.
- Wall Street gets insights and recommendations on major stock picks.
- Investors are paying attention to expert opinions for potential investment opportunities.
00
business 2024-08-20 00:00
Analysts See Growth Potential for Eli Lilly, Vista Energy, and AMD - Analysts predict growth potential for Eli Lilly, Vista Energy, and AMD.
- Positive outlook shared for these companies by analysts.
- Investors may consider these stocks for potential upside.
00
business 2024-08-20 00:00
Big Stock Moves: Eli Lilly, Paramount Global, and Palo Alto Networks - Eli Lilly, Paramount Global, and Palo Alto Networks experience significant stock movements.
- Premarket and midday trading see notable changes in stock values.
- Investors closely monitor the performance of these key companies.
00
business 2024-08-16 00:00
Stock Market Update: Eli Lilly Shows Positive Signs - Wall Street is lower Friday morning after a strong session Thursday.
- Eli Lilly shows positive signs in the stock market update.
- Investors are optimistic about Eli Lilly's performance.
00
business 2024-08-14 00:00
Eli Lilly Growing against Novo Nordisk - Eli Lilly gaining momentum in the weight loss drug market against Novo Nordisk.
- Stryker to acquire artificial intelligence startup Care.ai.
- Competition heating up in the GLP-1 market.
00
business 2024-08-14 00:00
Top Analyst Calls for Various Companies - Wall Street analysts have made significant calls on Nvidia, Tesla, Starbucks, and other companies.
- The calls are expected to impact the stock market and investors' decisions.
- Investors are advised to pay attention to the recommendations provided by the analysts.
00
business 2024-08-12 00:00
Eli Lilly's Strong Earnings Boosts Stock - Shares of Eli Lilly surged by approximately 8% following a strong earnings report.
- The company exceeded analyst expectations, which contributed to the stock increase.
- This positive performance highlights Eli Lilly's strong market position in the pharmaceutical industry.
00
business 2024-08-12 00:00
Cramer Urges Investors to Focus on Individual Stocks Over Macroeconomic Trends - Jim Cramer advised investors to consider individual company performance rather than solely relying on macroeconomic trends.
- This recommendation follows a promising report about Eli Lilly's success in the market.
- Investors are encouraged to take a more nuanced approach to portfolio decisions.
00
business, health 2024-08-12 00:00
Eli Lilly Shows Progress in Weight Loss Drug Zepbound - Eli Lilly has shown significant progress in its weight loss drug Zepbound, easing investor concerns.
- Analyst Mohit Bansal from Wells Fargo expressed relief over the recent results.
- The advancements may signal a positive trajectory for the drug's approval and market performance.
00
business 2024-08-12 00:00
Eli Lilly Sees Big Sales from Mounjaro and Zepbound - Eli Lilly reported over $4 billion in sales for Mounjaro and Zepbound, surpassing second-quarter expectations.
- This significant revenue boost highlights the growing market for diabetes and weight loss medications.
- Eli Lilly's success with these drugs positions the company strongly in the pharmaceutical industry.
00
2023 All rights reserved
2023 All rights reserved